Recently, DR. Rocklage was celebrated for contributing towards the renovation of Moungi Bawendi’s nanochemistry and nanotechnology lab space. He pursued his PhD studies at MIT Department of Chemistry under Professor Richard R. Schrock, the Nobel Prize Winner in chemistry. When the former head of the Chemistry Department approached Scott about the possibility of supporting the projects in the department, he immediately responded by asking about the most urgent need. His willingness to support MIT is a gratitude for giving him the platform to nurture his professional life and career in chemistry. Scott and his wife visited the department to celebrate the milestone.
After exploring the newly renovated lab space offered by Professor Bawendi and his two graduate students, He Wei and Whitney Hess, Bawendi group members and faculty converged at the lab’s vestibule to view the display of a plaque honoring the Rocklages. Timothy Jamison, the current Department Head, Sylvia Ceyer and Professor Moungi Bawendi paid their tribute to the Rocklages. The department’s 2010 newsletter featured Scott Rocklage as an alumnus profile where he said that he never knew his survivalist skills would be of great importance to MIT. He posited that he was lucky to be accepted in the department where he had a chance to associate with individuals having big intellects and visions. Scott attributed his success to the productive atmosphere of high competition, reagent, glove box time and Dick’s leadership. Scott also thanked his friends Howard Turner, Clayton Wood and Jere Fellman for their support while studying at MIT.
About Scott Rocklage
Scott Rocklage is a managing partner at 5AM Ventures, a company that he joined as a venture partner in 2003. He has over two decades of experience in the healthcare management industry. Over the years, Scott has provided transformative leadership to different organization. His engagement with different stakeholders has earned him extensive knowledge in healthcare. Through networking, Scott was able to obtain FDA approval of the three US new drugs, which are Omniscan™, Teslascan® and Cubicin® and entered six drug candidates into clinical trials.
His broad involvement in the healthcare management field saw him serve as the president and CEO of Nycomed Salutar. He has also worked as the chairman and CEO of Cubist Pharmaceuticals. In addition, Scott has been the president, chairman and CEO of Nycomed Interventional. He also assumed various R&D positions at Salutar and Catalyca. Scott heads the Board of Achaogen, Semprus and Relypsa. Owing to his extensive knowledge, different companies have enlisted his services. Scott is an active member of the board of WaveRx, board of associates at the Whitehead Institute, as well as Pulmatrix and Variation. He is an alumnus of the University of California, Berkley, and the Massachusetts Institute of Technology where he graduated with a B.S. and a PhD in Chemistry respectively.